Similar articles

• Risks and benefits of celecoxib to prevent recurrent adenomas.

  Psaty BM, Potter JD. Psaty BM, et al. N Engl J Med. 2006 Aug 31;355(9):950-2. doi: 10.1056/NEJMe068158. N Engl J Med. 2006. PMID: 16943408 No abstract available.
• New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs.

  Dubois RN. Dubois RN. Cancer Prev Res (Phila). 2009 Apr;2(4):285-7. doi: 10.1158/1940-6207.CAPR-09-0038. Epub 2009 Mar 31. Cancer Prev Res (Phila). 2009. PMID: 19336723 Review. No abstract available.
• Celecoxib for the prevention of colorectal adenomatous polyps.

  Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators. Arber N, et al. N Engl J Med. 2006 Aug 31;355(9):885-95. doi: 10.1056/NEJMoa061652. N Engl J Med. 2006. PMID: 16943401 Clinical Trial.
• Does celecoxib use increase the risk of cardiovascular events?

  Oviedo JA, Schroy PC 3rd. Oviedo JA, et al. Gastroenterology. 2005 Oct;129(4):1348-50. doi: 10.1053/j.gastro.2005.08.029. Gastroenterology. 2005. PMID: 16230088 No abstract available.
• COX-2 selective inhibitors and heart health.

  Simon LS, White WB. Simon LS, et al. Postgrad Med. 2005 Jan;117(1 Suppl):7-20. doi: 10.3810/pgm.01.2005.suppl40.201. Postgrad Med. 2005. PMID: 19667717 Review.